** Shares of drug developer Monte Rosa Therapeutics rise 37.22% to $6.84 ** Novartis will pay GLUE $150 million upfront for a global license to develop, manufacture and sell some drug candidates
** GLUE will also be eligible for future payments of up to $2.1 billion in development, regulatory, and sales milestones
** The agreement is expected to accelerate the development of MRT-6160, which is in an early-stage study for immune-mediated conditions
** GLUE stock up ~20% YTD
(Reporting by Sriparna Roy in Bengaluru) ((mailto:Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.